arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Adaptive Biotechnologies Corp

ADPT
$24.93 ▲ +1.34 (+5.68%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
11 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Adaptive Biotechnologies Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.8B
Dividend Yield
Revenue Growth 54.8%
Op. Margin -20.6%
ROIC -16.5%
FCF / Share $-0.32
Trailing P/E
Price / Book 17.5x
FCF Yield
Debt / Equity 0.58
info Valuation on last close. End-of-day price, Aug 7, 2026.

11-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$276.98M
↑ +54.8%
Net Income Profit after all expenses
$-59.50M
↑ +62.7%
Operating Margin Operating profit as % of sales
-20.6%
↑ +77.3% 10th
FCF / Share Free cash flow per share
$-0.32
↑ +52.0%
Long-Term Debt Long-term obligations
$126.57M
↓ -4.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
10
Returns
24
Financial Health
41
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 11 years · 36 quarters